Bio - so I was right that HALO and its shareholders and analysts have absolutely no idea whether the control arm patients may have higher PFS figures than the HALO patients. So why say it's not a blinded study when it is blinded to everyone except the administrators? So Helen was quite right in what she said. The way the share price has been moving recently makes me wonder whether there may be a problem with the control arm. It's not like it's never happened before.
News 
Market Data 
Discover 
